Trial Condition(s):

Venous Thromboembolism

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients with Cancer-Associated Thromboembolism Treated with Rivaroxaban

Bayer Identifier:

19622

ClinicalTrials.gov Identifier:

NCT03214172

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban

Inclusion Criteria
- Adult patients (≥18 years-of-age) with active cancer
- Patient with at least one index venous thromboembolism  (VTE )
- ≥6-months of continuous eligibility prior to the index VTE event (baseline period).
- Newly initiated on rivaroxaban
Exclusion Criteria
- Patients with any medical claim for Deep vein thrombosis (DVT) or Pulmonary embolism (PE) during the 6 months pre-index date 
- Patients with prescription claim for anticoagulation therapy during the 6-month pre-index VTE period

Trial Summary

Enrollment Goal
1000
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

US database

New York, United States, 10001

Status
Completed
 

Trial Design